1.
Clin Case Rep
; 5(8): 1226-1229, 2017 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28781829
RESUMO
Given the immune background, we hypothesize that active Grave's hyperthyroidism is a risk factor for an acute phase reaction associated with the use of bisphosphonates. We recommend that in patients with Graves' thyrotoxicosis and hypercalcemia, consider the risk of an acute phase reaction if planning to give bisphosphonate therapy.